Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06619860 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from Apr 30, 2026 to Mar 25, 2027 Completion pushed from May 30, 2026 to Apr 22, 2027v19 Show 1 more changeShow less
    • Completion pushed from May 30, 2026 to Apr 22, 2027
  2. Re-verified, no change to tracked fieldsv18
  3. Site details revised at 23 of 47 sitesv17
  4. Study sites: 46 to 47v16
  5. Study sites: 45 to 46v15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 43 to 45v14
  2. Study sites: 41 to 43v13
  3. Primary endpoints: 2 to 1 Study sites: 40 to 41 · Secondary endpoints: 3 to 4v12 Show 2 more changesShow less
    • Study sites: 40 to 41
    • Secondary endpoints: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 34 to 40v11
  5. Study sites: 31 to 34v10
  6. Primary endpoints: 1 to 2 Study sites: 27 to 31 · Secondary endpoints: 4 to 3v9 Show 2 more changesShow less
    • Study sites: 27 to 31
    • Secondary endpoints: 4 to 3

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites: 26 to 27v8
  8. Re-verified, no change to tracked fieldsv7
  9. Study sites: 24 to 26v6
  10. Study sites: 11 to 24 Primary completion date: Apr 2026 to Apr 30, 2026 · Completion date: May 2026 to May 30, 2026v5 Show 2 more changesShow less
    • Primary completion date: Apr 2026 to Apr 30, 2026
    • Completion date: May 2026 to May 30, 2026
  11. Study sites: 6 to 11v4
  12. Study sites: 5 to 6v3
  13. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 5 · Start date changed from estimate of Oct 2024 to Oct 18, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 5
    • Start date changed from estimate of Oct 2024 to Oct 18, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Trial Details
NCT Number NCT06619860
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Diabetic Peripheral Neuropathic Pain
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov